They also showed that RASAL2 was a functional target of anti-invasive mircroRNA-203, and RASAL2 expression was associated with poor clinical outcome, early metastasis and disease recurrence in patients with triple-negative breast cancer [14]. Here, RASAL2 is linked to triple-negative breast carcinoma.